Advertisement
Acrux Limited

Acrux Limited Fundamental Analysis

ACR.AXASX
HealthcareBiotechnology
$0.01
$0.00(0.00%)
Australian Market opens in 49h 1m
Advertisement

Acrux Limited Fundamental Analysis

Acrux Limited (ACR.AX) shows weak financial fundamentals with a PE ratio of -2.07, profit margin of -83.81%, and ROE of -2.12%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position19.20%
PEG Ratio-0.02

Areas of Concern

ROE-2.12%
Operating Margin-1.85%
We analyze ACR.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -335.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-335.0/100

We analyze ACR.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

ACR.AX struggles to generate sufficient returns from assets.

ROA > 10%
-49.76%

Valuation Score

Excellent

ACR.AX trades at attractive valuation levels.

PE < 25
-2.07
PEG Ratio < 2
-0.02

Growth Score

Weak

ACR.AX faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

ACR.AX shows balanced financial health with some risks.

Debt/Equity < 1
3.03
Current Ratio > 1
1.35

Profitability Score

Weak

ACR.AX struggles to sustain strong margins.

ROE > 15%
-211.88%
Net Margin ≥ 15%
-83.81%
Positive Free Cash Flow
No

Key Financial Metrics

Is ACR.AX Expensive or Cheap?

P/E Ratio

ACR.AX trades at -2.07 times earnings. This suggests potential undervaluation.

-2.07

PEG Ratio

When adjusting for growth, ACR.AX's PEG of -0.02 indicates potential undervaluation.

-0.02

Price to Book

The market values Acrux Limited at 4.11 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.11

EV/EBITDA

Enterprise value stands at -0.46 times EBITDA. This is generally considered low.

-0.46

How Well Does ACR.AX Make Money?

Net Profit Margin

For every $100 in sales, Acrux Limited keeps $-83.81 as profit after all expenses.

-83.81%

Operating Margin

Core operations generate -1.85 in profit for every $100 in revenue, before interest and taxes.

-1.85%

ROE

Management delivers $-2.12 in profit for every $100 of shareholder equity.

-2.12%

ROA

Acrux Limited generates $-49.76 in profit for every $100 in assets, demonstrating efficient asset deployment.

-49.76%

Following the Money - Real Cash Generation

Operating Cash Flow

Acrux Limited generates limited operating cash flow of $-5.35M, signaling weaker underlying cash strength.

$-5.35M

Free Cash Flow

Acrux Limited generates weak or negative free cash flow of $-5.35M, restricting financial flexibility.

$-5.35M

FCF Per Share

Each share generates $-0.01 in free cash annually.

$-0.01

FCF Yield

ACR.AX converts -1.14% of its market value into free cash.

-1.14%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.07

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.02

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.11

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.71

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

3.03

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.35

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-2.12

vs 25 benchmark

ROA

Return on assets percentage

-0.50

vs 25 benchmark

ROCE

Return on capital employed

-1.94

vs 25 benchmark

How ACR.AX Stacks Against Its Sector Peers

MetricACR.AX ValueSector AveragePerformance
P/E Ratio-2.0730.23 Better (Cheaper)
ROE-211.88%403.00% Weak
Net Margin-83.81%-11442.00% (disorted) Weak
Debt/Equity3.030.78 Weak (High Leverage)
Current Ratio1.354.98 Neutral
ROA-49.76%-248.00% (disorted) Weak

ACR.AX outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Acrux Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ